Axsome Therapeutics Forecasts $193M Quarter with +30% Earnings ESP
Axsome Therapeutics is projected to narrow its quarterly loss to $0.70 per share on revenues of $193.01 million, representing 62.5% year-over-year growth in Q4. Analysts have raised the EPS consensus by 7.1% over the past month, giving the stock a +30% Earnings ESP and a Zacks Rank of #3.
1. Q4 Estimates and Outlook
Axsome Therapeutics is expected to report a non-GAAP loss of $0.70 per share, a 27.1% improvement year-over-year, on projected revenues of $193.01 million, up 62.5% from the same quarter a year earlier.
2. Estimate Revisions and Earnings ESP
Analysts have lifted the quarterly EPS consensus by 7.1% over the past 30 days, resulting in an Earnings ESP of +30.0%, which signals an elevated probability of an earnings beat relative to consensus forecasts.
3. Historical Earnings Surprise
Over the last four reporting periods, Axsome has exceeded consensus EPS estimates three times; in the most recent quarter it missed by 14.6%, delivering a $0.94 loss versus a projected $0.82 loss.
4. Key Considerations Ahead of Release
Investors will focus on management commentary around marketed products Auvelity and Sunosi, updates on CNS pipeline trials, and cost trends given prior quarter expense pressures to gauge sustainability beyond any near-term beat.